){kind=logo}
An estimated 8 million people in the UK are suffering with OSA (obstructive sleep apnoea). Since 2014 more than 100,000 patients worldwide including a growing number of British OSA sufferers in the last few years have pursued restful sleep with Inspire therapy. This well studied and established therapy (over 350 publications) demonstrates significant AHI (Apnoea-Hypopnea Index) and quality of life improvements.
By working comfortably inside a patient’s body, Inspire helps to keep their airway open while they sleep so they can breathe regularly and sleep soundly. The Inspire® Upper Airway Stimulation (UAS) system stimulates the hypoglossal nerve, synchronous with respiration, to elicit a neuromuscular response at the base of the tongue and to maintain airway patency in patients with moderate to severe obstructive sleep apnoea (OSA).
Address
Neuer Wall 80Hamburg
20354
Germany
Contact Exhibitor
Products
-
)
Through hypoglossal nerve stimulation, Inspire therapy provides a safe and effective alternative for moderate to severe OSA patients who cannot tolerate using CPAP. Over 100,000 patients worldwide hav ...
News
-
)
Inspire Medical Systems Europe GmbH, a medical technology company focused on the development of innovative, minimally invasive solutions for obstructive sleep apnoea, today announced eight major NHS h ...
